Focus: Microbix Biosystems is a public diagnostics and viral vector company specializing in antigen production and molecular diagnostics, with a legacy gene therapy platform.
Profile data last refreshed 17h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Microbix Biosystems to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Microbix Biosystems's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Low molecular weight urokinase fibrinolytic approved as a BLA; patent cliff imminent with no disclosed generic competition plan.
Help build intelligence for Microbix Biosystems
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Microbix Biosystems Inc (MBXBF) (Q3 2026) Earnings Call Highligh - GuruFocus
Microbix Biosystems Inc (MBXBF) (Q3 2026) Earnings Call Highligh GuruFocus
Headline: Microbix Biosystems Stock Slides 6.45% as Recovery Uncertainty Raises Downside Risk - kalkine.ca
Headline: Microbix Biosystems Stock Slides 6.45% as Recovery Uncertainty Raises Downside Risk kalkine.ca
Microbix Biosystems Stock Rises 3.33% as Investors Weigh Diagnostic Testing Growth, Quality Assessment Products and Biotech Expansion - kalkine.ca
Microbix Biosystems Stock Rises 3.33% as Investors Weigh Diagnostic Testing Growth, Quality Assessment Products and Biotech Expansion kalkine.ca
Knight Therapeutics Stock Jumps 4.94% as Investors Weigh Specialty Pharma Growth, Latin American Expansion and Drug Portfolio Execution - kalkine.ca
Knight Therapeutics Stock Jumps 4.94% as Investors Weigh Specialty Pharma Growth, Latin American Expansion and Drug Portfolio Execution kalkine.ca
Microbix Biosystems says ‘agressively pursuing’ new client programs - TipRanks
Microbix Biosystems says ‘agressively pursuing’ new client programs TipRanks
Apotex Health Stock Drops 3.94% as Investors Weigh Post-IPO Valuation, Generic Drug Growth and U.S. Expansion - kalkine.ca
Apotex Health Stock Drops 3.94% as Investors Weigh Post-IPO Valuation, Generic Drug Growth and U.S. Expansion kalkine.ca
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moRecent peer-reviewed publications with author affiliations at this company
MicroRNAs as prognostic and predictive biomarkers among chronic myeloid leukemia patients in Addis Ababa, Ethiopia.
Hematological, clinical, cytogenetic and molecular profiles of confirmed chronic myeloid leukemia patients at presentation at a tertiary care teaching hospital in Addis Ababa, Ethiopia: a cross-sectional study.